Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

854
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
854
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

302
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
302
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

447
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
447

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: Potential innovation against Alzheimer's disorder: a tricomponent combination of natural antioxidants (vitamin E, quercetin, and basil oil) and the development of its intranasal delivery.

Environmental science and pollution research international·2026
Same author

Molecular carcinogenesis and genetic insights in leiomyosarcoma: involvement of PI3K/AKT/mTOR/MAPK/ERK pathway.

American journal of cancer research·2026
Same author

Harnessing Neuronal Autophagy: Bridging Mechanistic Breakthroughs to Therapeutic Interventions.

Aging and disease·2026
Same author

Genes and physiological strategies in bacterial antibiotic resistance.

Frontiers in microbiology·2026
Same author

Correction: Mitochondrial-mediated apoptosis as a therapeutic target for FNC (2'-deoxy-2'-b-fluoro-4'-azidocytidine)-induced inhibition of Dalton's lymphoma growth and proliferation.

Discover oncology·2026
Same author

Gender-specific perspectives in schizophrenia: Recent advances and future directions.

Progress in neuro-psychopharmacology & biological psychiatry·2026

Related Experiment Video

Updated: Oct 19, 2025

Synergetic Use of Neural Precursor Cells and Self-assembling Peptides in Experimental Cervical Spinal Cord Injury
11:57

Synergetic Use of Neural Precursor Cells and Self-assembling Peptides in Experimental Cervical Spinal Cord Injury

Published on: February 23, 2015

9.4K

Peptide Based Therapy for Neurological Disorders.

Asmita Yadav1, Damini Pandey1, Ghulam Md Ashraf2

  • 1Department of Biotechnology, Jaypee Institute of Information Technology, JIIT Noida, Sector 62, Noida-201309, UP,India.

Current Protein & Peptide Science
|September 21, 2021
PubMed
Summary

Peptides show great potential for treating neurodegenerative disorders (NDDs) and other diseases. Research focuses on developing novel peptide therapeutics, improving their safety, and exploring new applications beyond NDDs.

Keywords:
Alzheimer’s diseaseHuntington’s diseaseParkinson’s diseasedentatorubral-paiidoluysial atrophypeptidestherapy.

More Related Videos

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.7K
A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
10:42

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

9.5K

Related Experiment Videos

Last Updated: Oct 19, 2025

Synergetic Use of Neural Precursor Cells and Self-assembling Peptides in Experimental Cervical Spinal Cord Injury
11:57

Synergetic Use of Neural Precursor Cells and Self-assembling Peptides in Experimental Cervical Spinal Cord Injury

Published on: February 23, 2015

9.4K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.7K
A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
10:42

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

9.5K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Neuroscience

Background:

  • Peptides, small molecules of amino acids, offer targeted delivery for disease modification.
  • Neurodegenerative Disorders (NDDs) are a significant focus for peptide therapeutics, including natural and synthetic options.
  • Peptide-based vaccines and drug development face challenges like toxicity and haemolytic activity, necessitating structural modifications.

Purpose of the Study:

  • To review recent advancements in peptide therapeutics for neurodegenerative diseases.
  • To highlight novel peptides discovered for treating NDDs and other conditions.
  • To discuss the potential and challenges of peptide-based drug development.

Main Methods:

  • Review of current literature on peptide therapeutics for NDDs.
  • Identification of key peptide inhibitors and their mechanisms (e.g., Aβ (16-20) KLVFF, NAPVSIPQ, VIP, QBP1, Ba-V).
  • Exploration of bioinformatics tools like High Throughput Screening (HTS) for peptide discovery and characterization.

Main Results:

  • Several peptides are effective inhibitors for specific NDDs like Alzheimer's, Parkinson's, Huntington's, and DRPLA.
  • Peptides inhibiting Mitochondrial Permeability Transition (MPT) show promise in NDD treatment.
  • Bioinformatics tools are crucial for identifying selective, stable, and safe therapeutic peptides.

Conclusions:

  • Peptide therapeutics hold significant promise for treating neurodegenerative disorders and other diseases like cancer and diabetes.
  • Ongoing research aims to overcome toxicity and enhance efficacy through peptide modification and advanced discovery methods.
  • The versatility of peptides makes them a rapidly evolving area of therapeutic development.